Stocks
Cara Therapeutics (CARA) EBITDA US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA, bln rub | ? | -88.2 | -83.8 | -117.7 | -62.6 | 0.095 | -33.4 | ||
| Changes by years, y/y, % | -1 677% | -5% | +40% | -47% | -100% | -55.7% | |||
Cara Therapeutics. EBITDA US GAAP, bln rub
Cara Therapeutics. EBITDA US GAAP, changes, %
Cara Therapeutics. EBITDA US GAAP, sum by quarters, bln rub
Cara Therapeutics (CARA) EBITDA US GAAP (quarter values) |
||||||||
| FY2025Q1 | FY2025Q2 | FY2025Q3 | FY2025Q4 | FY2026Q1 | LTM ? | |||
| EBITDA, bln rub | ? | 0.000 | 4.21 | -5.50 | 1.38 | 0.024 | -33.4 | |
| Changes by years, y/y, % | -100% | -123% | -47% | -125% | ||||
| Changes by quarters, q/q, % | -100% | -231% | -125% | -98% | ||||
